CBD: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
VisualWikitext
No edit summary
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 10: Line 10:
|notes=CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers,  
|notes=CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers,  
conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
Recent research into the use of CBD (cannabidiol) for treating glioblastoma has shown promising results, particularly in its potential impact on overall survival (OS). One study found that CBD, due to its anti-inflammatory properties, was able to reduce the size of glioblastoma tumors and improve the tumor microenvironment. This effect could potentially enhance the efficacy of standard treatments such as radiation and chemotherapy. However, most of these results have been observed in preclinical models, and more robust human trials are required to fully understand the OS benefits.<ref name="ScienceDaily">{{Cite web |title=CBD reduces glioblastoma’s size, supportive environment in experimental model |url=https://www.sciencedaily.com/releases/2021/12/211223141935.htm |publisher=ScienceDaily |date=2021-12-23 |accessdate=2024-08-12}}</ref><ref name="MayoClinic">{{Cite web |title=Fighting glioblastoma - one of the deadliest forms of brain cancer |url=https://cancerblog.mayoclinic.org/2024/05/02/fighting-glioblastoma-one-of-the-deadliest-forms-of-brain-cancer/ |publisher=Mayo Clinic |date=2024-05-02 |accessdate=2024-08-12}}</ref>


Additionally, a UK-based Phase II clinical trial, known as the ARISTOCRAT trial, is currently investigating the effects of Sativex, an oral spray containing both CBD and THC, combined with chemotherapy, on patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, which led to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.<ref name="BrainTumourCharity">{{Cite web |title=Phase 2 trial of cannabis-based drug in glioblastomas to open in summer 2022 |url=https://www.thebraintumourcharity.org/news/phase-2-trial-cannabis-based-drug-glioblastomas-open-summer-2022/ |publisher=The Brain Tumour Charity |date=2022-11-25 |accessdate=2024-08-12}}</ref>
=== Sativex (Nabiximols) and Glioblastoma ===
A Phase 1b trial investigated the combination of Sativex (nabiximols), a cannabis-based spray containing a 1:1 ratio of CBD and THC, with temozolomide (TMZ) chemotherapy in patients with recurrent glioblastoma. The study observed a significant improvement in one-year survival rates among patients treated with Sativex compared to the placebo group (83% versus 44%, respectively). This difference suggests that Sativex could enhance survival when combined with standard chemotherapy. However, researchers emphasize that these findings, while promising, need to be confirmed in larger, more robust clinical trials.<ref>{{Cite web |title=Clinical Trial: CBD
Doubles Brain Cancer Survival Rates |url=https://mysupplyco.com |publisher=My Supply Co. |accessdate=2024-08-12}}</ref>
 
=== Potential Mechanisms and Future Research ===
The effects of CBD in glioblastoma are thought to stem from its ability to inhibit tumor cell migration, invasion, and angiogenesis. CBD has shown potential in modulating the immune environment around the tumor, possibly enhancing the effectiveness of other treatments like chemotherapy. These preclinical findings, along with the initial clinical results, suggest a multi-targeted approach by CBD that could be beneficial in treating glioblastoma.<ref>{{Cite web |title=From bench to bedside: the application of cannabidiol in glioma |url=https://translational-medicine.biomedcentral.com |publisher=Journal of Translational Medicine |accessdate=2024-08-12}}</ref>
 
Further research, including ongoing and future trials, is necessary to fully understand the impact of CBD and THC-based treatments on overall survival in glioblastoma patients and to determine the best protocols for their use.<ref>{{Cite web |title=Developments in cannabis-based drug trial for glioblastomas |url=https://www.thebraintumourcharity.org |publisher=The Brain Tumour Charity |accessdate=2024-08-12}}</ref>


These studies represent a growing interest in the potential of cannabinoids as a supplementary treatment for glioblastoma, but while early results are promising, further research is essential to establish clear OS benefits.


|category=Nutraceuticals
|category=Nutraceuticals

Latest revision as of 13:10, 12 August 2024

Property Information
Drug Name CBD (Cannabidiol)
FDA Approval Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment
Used for Investigational use in cancer treatment, including symptom management and potential anti-tumor effects
Clinical Trial Phase Preclinical studies and early human trials for cancer
Clinical Trial Explanation Not specified
Common Side Effects Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy
OS without Not specified
OS with Not applicable; ongoing research into potential impacts on overall survival in cancer patients
PFS without Not specified
PFS with Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.

Notes: CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers, conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.

Sativex (Nabiximols) and Glioblastoma

A Phase 1b trial investigated the combination of Sativex (nabiximols), a cannabis-based spray containing a 1:1 ratio of CBD and THC, with temozolomide (TMZ) chemotherapy in patients with recurrent glioblastoma. The study observed a significant improvement in one-year survival rates among patients treated with Sativex compared to the placebo group (83% versus 44%, respectively). This difference suggests that Sativex could enhance survival when combined with standard chemotherapy. However, researchers emphasize that these findings, while promising, need to be confirmed in larger, more robust clinical trials.<ref>Template:Cite web</ref>

Potential Mechanisms and Future Research

The effects of CBD in glioblastoma are thought to stem from its ability to inhibit tumor cell migration, invasion, and angiogenesis. CBD has shown potential in modulating the immune environment around the tumor, possibly enhancing the effectiveness of other treatments like chemotherapy. These preclinical findings, along with the initial clinical results, suggest a multi-targeted approach by CBD that could be beneficial in treating glioblastoma.<ref>Template:Cite web</ref>

Further research, including ongoing and future trials, is necessary to fully understand the impact of CBD and THC-based treatments on overall survival in glioblastoma patients and to determine the best protocols for their use.<ref>Template:Cite web</ref>


From Ben Williams Book: Not specified

Loading comments...


Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=CBD&oldid=88789"